Genotoxicity Genotype Marketing 
The Pharma Data
MARCH 25, 2021
The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. including final safety information for prescribers) will be assessed as part of ongoing and future Marketing Authorization Applications.
The Pharma Data
APRIL 7, 2021
The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. The incidence of Grade 3-4 neutropenia in genotyped patients was 69% in patients homozygous for the UGT1A1*28, 48% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele.
Expert insights. Personalized for you.
52 
Let's personalize your content